title: Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
authors.affiliation: Duke Clinical Research Institute, P.O. Box 17969, Durham, NC 27715, USA.
authors.forename: K R
authors.initials: KR
authors.lastname: Campbell
authors.forename: K W
authors.initials: KW
authors.lastname: Mahaffey
authors.forename: B E
authors.initials: BE
authors.lastname: Lewis
authors.forename: J I
authors.initials: JI
authors.lastname: Weitz
authors.forename: S D
authors.initials: SD
authors.lastname: Berkowitz
authors.forename: E M
authors.initials: EM
authors.lastname: Ohman
authors.forename: R M
authors.initials: RM
authors.lastname: Califf
mesh_terms: D000787:Angina Pectoris / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods; D000925:Anticoagulants / Q000009:adverse effects*; D000991:Antithrombins / Q000627:therapeutic use*; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control; D006493:Heparin / Q000009:adverse effects*; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives*; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012449:Safety; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin; C074619:bivalirudin